Join our daily newsletter At The Bell to receive exclusive market insights
- Mental health tech company Medibio (MEB) has been granted a patent by the U.S. Patent and Trademark Office
- The patent is titled ‘Method and System for Monitoring Stress Conditions’ and relates machine learning that monitors stress conditions by analysing heart rate data collected before, during and after sleep
- This patent will be instrumental in protecting Medibio’s mental well-being program, ilumen, and its consumer app, which is currently under development
- Medibio is now in the process of reviewing the scope of existing patents and will advise the market of any findings
- Company shares are steady on the market this morning and are trading for 1.2 cents each
Mental health tech company Medibio (MEB) has been granted a patent by the U.S. Patent and Trademark Office.
The patent is titled ‘Method and System for Monitoring Stress Conditions’ and relates machine learning that monitors stress conditions by analysing heart rate data collected before, during and after sleep.
This patent will be instrumental in protecting Medibio’s mental well-being program, ilumen, and its consumer app, which currently under development.
ilumen is a program which provides data feedback to help employees improve their mental well-being.
It assesses the user’s wellness by conducting surveys which track much sleep they are getting, their exercise patterns and work hours. The user will receive their results with recommendations on coping strategies and a personal development plan.
Medibio is now in the process of reviewing the scope of existing patents and will advise the market of any findings.
Company shares are steady on the market and are trading for 1.2 cents each at 11:19 am AEST.
